GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amneal Pharmaceuticals Inc (STU:2DT) » Definitions » Capex-to-Revenue

Amneal Pharmaceuticals (STU:2DT) Capex-to-Revenue : 0.03 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Amneal Pharmaceuticals Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Amneal Pharmaceuticals's Capital Expenditure for the three months ended in Mar. 2024 was €-18.18 Mil. Its Revenue for the three months ended in Mar. 2024 was €606.46 Mil.

Hence, Amneal Pharmaceuticals's Capex-to-Revenue for the three months ended in Mar. 2024 was 0.03.


Amneal Pharmaceuticals Capex-to-Revenue Historical Data

The historical data trend for Amneal Pharmaceuticals's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amneal Pharmaceuticals Capex-to-Revenue Chart

Amneal Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial 0.06 0.03 0.03 0.04 0.03

Amneal Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.02 0.02 0.05 0.03

Competitive Comparison of Amneal Pharmaceuticals's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Amneal Pharmaceuticals's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amneal Pharmaceuticals's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amneal Pharmaceuticals's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Amneal Pharmaceuticals's Capex-to-Revenue falls into.



Amneal Pharmaceuticals Capex-to-Revenue Calculation

Amneal Pharmaceuticals's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-63.446) / 2194.938
=0.03

Amneal Pharmaceuticals's Capex-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-18.179) / 606.456
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amneal Pharmaceuticals  (STU:2DT) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Amneal Pharmaceuticals Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Amneal Pharmaceuticals's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Amneal Pharmaceuticals (STU:2DT) Business Description

Traded in Other Exchanges
Address
400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ, USA, 08807
Amneal Pharmaceuticals Inc is a generic pharmaceutical manufacturer. The company's reportable segments are Generic Products, Specialty products, and AvKARE. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals, and the Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies.

Amneal Pharmaceuticals (STU:2DT) Headlines

No Headlines